ICML 2023 | DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL
Won-Seog Kim
• 16 Jun 2023
Won-Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, South Korea, shares an update on the Phase II DISTINKT study (NCT04414163) of IMC-001, an anti-PD-L1 checkpoint inhibitor, in patients with relapsed/refractory extranodal NK/T-cell lymphoma (R/R ENKTCL). Prof. Kim comments on the success of immunologic agents in ENKTCL before sharing the patient response data from the interim analysis of the trial. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
